Suppr超能文献

是时候在国家免疫规划中引入乙肝加强疫苗了吗?基于现有证据的分析。

Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence.

作者信息

Bhattacharya Sudip, Gökdemir Özden, Bashar Md Abu, Thiyagarajan Arulmani, Singh Amarjeet

机构信息

Department of Community Medicine, Himalayan Institute of Medical Sciences, Dehradun, Uttarakhand, India.

Izmir University of Economics, Faculty of Medicine, Izmir, Turkey.

出版信息

Indian J Community Med. 2021 Jan-Mar;46(1):4-6. doi: 10.4103/ijcm.IJCM_439_19. Epub 2021 Mar 1.

Abstract

Hepatitis B virus (HBV) infection is a global health concern, and it is considered one of the deadliest infections in the world, having nearly 1.2 million deaths annually. Around 75% of all global HBV carriers live in the Asia-Pacific region. In this regard, India has a prevalence ranging between 2% and 7% with exposure rates of 10%-60%. Hepatitis B is a vaccine-preventable disease. In India, the World Health Organization protocol for hepatitis B vaccination has been followed, and it is given free of cost in public health facilities under the National Immunization Schedule. Despite the free hepatitis vaccination program in India, coverage and awareness are low. Low awareness, followed by low coverage of hepatitis vaccination, can prove dangerous for the Indian population in the long run. A majority of chronic hepatitis cases progress silently to end-stage liver disease without having many signs and symptoms. Once occurred, a complete cure is not possible with currently available drugs. The studies from neighboring countries such as China and Taiwan documented that the impact of single-dose booster for children of 10 years has made a significant difference from the cost-effectiveness perspective. They have also included the booster dose in their national vaccination program. Considering the low level of vaccination awareness, small coverage, high disease burden, and high treatment cost, now, it is high time for India to introduce hepatitis B booster vaccine.

摘要

乙型肝炎病毒(HBV)感染是一个全球卫生问题,被认为是世界上最致命的感染之一,每年导致近120万人死亡。全球约75%的HBV携带者生活在亚太地区。在这方面,印度的患病率在2%至7%之间,暴露率为10%至60%。乙型肝炎是一种可通过疫苗预防的疾病。在印度,遵循了世界卫生组织的乙型肝炎疫苗接种方案,并且在国家免疫规划下的公共卫生机构免费提供。尽管印度有免费的肝炎疫苗接种计划,但覆盖率和知晓率较低。知晓率低,再加上肝炎疫苗接种覆盖率低,从长远来看可能对印度人口构成危险。大多数慢性肝炎病例会在没有太多体征和症状的情况下悄然发展为终末期肝病。一旦发生,目前可用的药物无法实现完全治愈。来自中国和台湾等邻国的研究表明,从成本效益角度来看,对10岁儿童进行单剂量加强免疫产生了显著差异。他们还将加强剂量纳入了国家疫苗接种计划。考虑到疫苗接种知晓率低、覆盖率小、疾病负担高和治疗成本高,现在印度是时候引入乙型肝炎加强疫苗了。

相似文献

本文引用的文献

7
Strategy vaccination against Hepatitis B in China.中国的乙型肝炎策略性疫苗接种
Hum Vaccin Immunother. 2015;11(6):1534-9. doi: 10.4161/21645515.2014.980206.
8
Tackling the Hepatitis B Disease Burden in India.应对印度的乙肝疾病负担
J Clin Exp Hepatol. 2014 Dec;4(4):312-9. doi: 10.1016/j.jceh.2014.12.004. Epub 2014 Dec 15.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验